Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin’s Lymphomas

Abstract

1. Utilize new therapeutic agents with proven efficacy in the chemotherapy-and monoclonal antibody-refractory NHL setting.2. Analyze the study of these new agents in lymphoma subtypes and in relation to genetic aberrations of the lymphoma.3. Differentiate the toxicity of these new agents from that of chemotherapy.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTThe availability of active monoclonal antibodies, either as single agents or in combination with cytotoxic agents, has improved treatment results in non-Hodgkin's lymphoma (NHL). Despite this and the increasing number of available active monoclonal antibodies, alone or conjugated with radioisotopes, not all types of lymphoma are sensitive to these biological agents and often they become resistant because of different molecular mechanisms.New molecular targets in neoplastic cells are emerging and provide the rationale for novel discovery initiatives. In fact, a greater knowledge of the biology of lymphoma and the identification of compounds selectively active against a potential therapeutic pathway have already improved the time to progression and survival time of patients with some subtypes of NHL. The growing list of new drugs provides the exciting prospect of developing disease-specific and even patient-specific therapies.The aim of this review is to identify and discuss nonmonoclonal antibody new therapeutic agents in terms of mechanism of action and clinical results. The preclinical and clinical features of proteasome inhibitors, histone deacetylase inhibitors, thalidomide and lenalidomide,

Immunological and molecular genetic mechanisms of the development of mycosis fungoides

“…Гиперэкспрессия HDACs наблюдается при многих опухолевых заболеваниях, в том числе и при ГМ. В настоящее время синтезированы ингибиторы HDACs, которые используются в терапии ТКЛК, проводятся исследования для создания новых, более эффективных форм ингибиторов HDACs [69].…”

Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles

“…Mantle cell lymphoma (MCL) represents a subgroup of poor prognostic, high-risk NHL with an aggressive biology and short progression-free as well as overall survival (1-3). Therefore, identification and evaluation of active new agents and new drug combinations against MCL (4-8), including exploratory single agent Phase II clinical studies in relapsed or refractory MCL (4,9-16), as well as more intense multimodality strategies with immunochemotherapy and hematopoietic stem cell transplantation for eligible patients (17,18), have been focal points in translational lymphoma research (3). Likewise, several research teams have embarked upon molecular target discovery efforts to identify new druggable targets in MCL cells using integrated multi-platform laboratory and in silico research tools (19-22).…”

Nanopharmacology in translational hematology and oncology

“…[175][176][177][178] SYK is a new target for the management of B-lineage leukemias and lymphomas, 179 as it regulates apoptosis by controlling activation of the phosphoinositide 3-kinase/AKT, nuclear factor-kappa B, and signal transducer and activator of transcription 3 pathways, which are all very important in the signaling of the stem cell lineage. 180,181 Cely et al 182 reported a different approach by developing a nanotechnology-based platform that can be used to target a very selective SYK inhibitor for the lymphoma cell.…”